Citius Pharmaceuticals Inc (CTXR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.30 Million) by net assets ($69.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Citius Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Citius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CTXR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Citius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Destinasi Tirta Nusantara Tbk
JK:PDES
|
0.250x |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
-0.733x |
|
Immo Mcc NV
BR:MCC
|
N/A |
|
Madhav Copper Limited
NSE:MCL
|
0.181x |
|
G3 Global Bhd
KLSE:7184
|
-0.010x |
|
Elbit Imaging Ltd
TA:EMITF
|
0.117x |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
-1.457x |
Annual Cash Flow Conversion Efficiency for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Citius Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $77.53 Million | $-26.55 Million | -0.342x | +10.01% |
| 2024-09-30 | $74.10 Million | $-28.20 Million | -0.381x | -19.74% |
| 2023-09-30 | $91.43 Million | $-29.06 Million | -0.318x | -15.91% |
| 2022-09-30 | $103.43 Million | $-28.36 Million | -0.274x | -50.15% |
| 2021-09-30 | $132.78 Million | $-24.25 Million | -0.183x | +63.68% |
| 2020-09-30 | $33.67 Million | $-16.93 Million | -0.503x | +1.44% |
| 2019-09-30 | $24.38 Million | $-12.44 Million | -0.510x | -25.61% |
| 2018-09-30 | $27.87 Million | $-11.32 Million | -0.406x | -11.83% |
| 2017-09-30 | $21.95 Million | $-7.97 Million | -0.363x | -3.20% |
| 2016-09-30 | $16.77 Million | $-5.90 Million | -0.352x | -109.37% |
| 2015-09-30 | $-635.21K | $-2.39 Million | 3.755x | +295.18% |
| 2014-09-30 | $-741.93K | $-705.05K | 0.950x | +530.18% |
| 2013-09-30 | $93.27K | $-20.60K | -0.221x | -149.83% |
| 2012-09-30 | $-45.85K | $-20.32K | 0.443x | -49.14% |
| 2011-09-30 | $-23.84K | $-20.78K | 0.872x | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more